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Abstract 
Background: Studies have been reported that cyclin‑dependent kinase5 (CDK5) was associated with the develop‑
ment of several cancers. However, the relationship between CDK5 level and clinicopathological factors is still poorly 
understood in cervical diseases. The aim of the current study was to investigate the expression of CDK5 and its clinical 
significance in variant cervical lesions.
Methods: Immunohistochemistry (IHC) was used to detect CDK5 expression in 54 cases of chronic cervicitis, 42 
cases of condyloma acuminate (CA), 38 cases of carcinoma in situ, and 360 cases of cervical cancers [adenocarcinoma, 
n = 63; squamous cell carcinoma (SCC), n = 263; adenosquamous carcinoma, n = 34]. The clinicopathological charac‑
teristics in relation to CDK5 were examined by Pearson’s Chi‑square test.
Results: The positive rates of CDK5 were 27.8, 31.0, 50, 54.0, 58.8, and 62.7 % in chronic cervicitis, CA, carcinoma 
in situ, adenocarcinoma, adenosquamous carcinoma and SCC, respectively. Statistically analysis showed that CDK5 
expression in cervical cancer tissues was higher than non‑cervical cancer tissues (inflammation and CA) (P < 0.001). 
The overexpression of CDK5 was significantly correlated with lymph node metastasis (r = 0.317; P < 0.001), histo‑
logical type (r = 0.198; P < 0.001), FIGO stage (r = 0.358; P < 0.001), TNM stage (r = 0.329; P < 0.001) and pathologi‑
cal grade (r = 0.259; P < 0.001) in cervical lesions evaluated by Pearson’s Chi‑square test. Furthermore, the positive 
relationships were found between CDK5 and lymph node metastasis (P < 0.001), FIGO stage (P < 0.001), TNM stage 
(P < 0.001) and pathological grade (P < 0.001) in SCC. CDK5 was positively interrelated to TNM stage (P = 0.017) in 
adenosquamous carcinoma.
Conclusions: CDK5 may play a vital role in the development of cervical cancer, which may be a marker for the diag‑
nosis, therapy and prognosis of cervical cancer.
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Background
According to GLOBOCAN 2012, cervical cancer is the 
fourth most frequent cancer after breast, colorectal 
and lung cancer in women and there were an estimated 
527,600 new cervical cancer cases and 265,700 deaths 
worldwide in 2012 [1]. In China, it was demonstrated that 
there were 98.9 per 100, 000 female diagnosed as cervi-
cal cancer and 30.5 per 100, 000 died from this disease in 
2015 [2]. Also, a project exploring the cancer survival in 
67 countries reported that the 5-year survival range was 
less than 50  % to more than 70  % of the world and the 
rate of 5-year survival was increased (from 40 to 60 %) in 
China [3].
Currently, surgical removal and radiotherapy are the 
main treatments for cervical cancer. Unfortunately, a 
tiny percentage of patients with cervical cancer in early 
stage disease can receive timely diagnosis and efficient 
treatment. Worse still, patients have a poor survival rate, 
with an expected 5-year survival of less than 10  % [4]. 
A Thai case study indicated that high burden and other 
factors may influence the screening services of cervical 
cancer [5]. These outcomes strongly suggest the require-
ment of innovative research to explore new approaches 
to the diagnosis and treatment in the early stage of cervi-
cal cancer. Cyclin-dependent kinase 5 (CDK5), a proline-
directed serine/threonine kinase, belongs to the CDK 
family activated by its regulators p35 or p39 [6]. Studies 
have reported that CDK plays a chief role in the cell cycle 
by regulating cell growth, differentiation, movement and 
apoptosis, and is closely related to the occurrence, devel-
opment and metastasis of tumor [7–10].
However, the relationship between CDK5 level and 
clinicopathological factors is still poorly understood in 
cervical diseases. To our knowledge, only two studies 
have investigated the relationship between CDK5 and 
HeLa cells, a type of cervical cancer cell line due to infec-
tion by human papilloma virus (HPV), which found that 
CDK5 might have an effect on the apoptosis of HeLa cells 
[11, 12]. To date, no study has been available to investi-
gate the expression and clinicopathological significance 
of CDK5 expression in cervical cancer tissues. Thus, 
in this study, we aimed to investigate the expression 




We retrospectively analyzed 512 operated cases at the 
first affiliated hospital of Guangxi Medical University 
over a period of January, 2011–December, 2014. Fifty-
six cases were excluded for the following criteria: If the 
size of the tissue was too small (diameter  <0.5  cm), we 
excluded it to keep the clinical evidence for diagnosis. 
Moreover, tissues falling out of the slide were also 
excluded in the process of immunohistochemistry. And 
only 360 cases of cervical cancer and 134 cases of non- 
cervical cancer were selected in the paper.
Cases of cervical cancer were staged according to the 
International Federation of Gynecology and Obstetrics 
(FIGO) 2009 [13] (stage I, n = 248; stage II, n = 16; stage 
III–IV, n = 96). Pathology grading was according to the 
World Health Organization (WHO) criteria [14] (grade I, 
n = 28, grade II, n = 157, grade III, n = 141) and tumor 
node metastasis (TNM) stage was according to American 
Joint Committee on Cancer (AJCC) Cervix Uteri Cancer 
Staging 7th edition [15] (stage 0, n = 38, stage I, n = 248, 
stage II–IV, n =  112). Ninety six of 360 cervical cancer 
cases had lymph node metastases. None of the cases 
received radiotherapy or chemotherapy. All the patients 
agreed to participate in this study and institutional 
review board-approved written cones were provided by 
patients before study entry. The study was approved by 
the Ethics Committee of the First Affiliated Hospital of 
Guangxi Medical University (Nanning, Guangxi, China) 
(NO. 2013/2016-KY-GUOJI-136).
Immunohistochemical staining to detect CDK5
In this study, immunohistochemistry (IHC) was per-
formed on tissue-microarrays. The pathological diag-
nosis was confirmed after the tissue was removed by 
surgical operation or tissue biopsy, and the tissue was 
fixed with neutral-buffered formalin (10 %) and the fixa-
tion time was 24–48 h according to the tissue size. IHC 
staining for CDK5 was performed on 4 µm thick paraf-
fin sections obtained from all cervical tissues in paraffin 
embedded blocks and conducted HE staining and histo-
logical observation. Slices were dealt with high pressure 
hotfix, immunohistochemical PV and DAB chromogenic 
and hematoxylin retying, hydrochloric acid-alcohol dif-
ferentiation, anhydrous ethanol dehydration, neutral gum 
sealing piece. Immunostaining for CDK5 was performed 
using CDK5 rabbit monoclonal antibody (Abeam, Clone 
ID: EP715Y; 1:50 dilution) and immunohistochemical kit 
was purchased from Beijing jinqiao biological co. LTD. 
All steps for immunohistochemical detection of CDK5 
were strictly operated according to the kit instructions. 
PBS of 0.01 mol/L (pH7.4) was used as a negative control. 
The sections were examined under a light microscope 
and claybank granules showed in the tissue were consid-
ered as positive CDK5 expression.
Immunohistochemical scoring
CDK5 expression was divided into negative group 
and positive group. The immunohistochemical stain-
ing was assessed by three authors (Yi-Wu  Dang, Kang-
Lai  Wei and Gang Chen) and an agreement regarding 
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controversial case was reached at a multithreaded micro-
scope. CDK5 score was determined by both intense stain-
ing and positive cell amounts in tumor tissues. CDK5 
expression was classified semi quantitatively according to 
the following criteria: no staining was recorded as 0; weak 
staining presenting as focal or fine granular was noted as 
1; strong staining with linear or cluster pattern was 2 and 
diffuse, intense staining was regarded as 3. The positive 
cell amounts in the tissue sample ranged from 0 to 3 in 
percentage: no staining was 0; <30 % was 1; 30–70 % was 
2 and >70 % was 3. The samples were categorized as posi-
tive and negative based on the sum of the scores as fol-
lows: 0–2: negative (−); 3–6: positive (+).
Statistical analysis
The statistical package SPSS version 20.0 (SPSS Inc, 
Chicago, illions, USA) was used to study the relation-
ship between the differential expression of CDK5 and 
clinicopathological parameters of cervical tissues. Two 
independent-samples Chi-square test and Kruskal–Wal-
lis H test were used to analyze the differences between 
groups. The correlation between CDK5 and clinicopatho-
logical characteristics should be assessed by Pearson’s 
Chi-square test. A P value of <0.05 was considered statis-
tically significant.
Results
The expression of CDK5 in cervical tissues
A total of 494 cervical specimens which were selected, 
including 54 cases of chronic cervicitis, 42 cases of CA, 38 
cases of carcinoma in situ and 360 cases of cervical can-
cers (adenocarcinoma, n = 63; squamous cell carcinoma 
(SCC), n = 263; adenosquamous carcinoma, n = 34). The 
patients aged from 19 to 82 years (median 44 years). Clin-
icopathological information of the patients was available 
in Tables 1, 2, 3, 4 and 5.    
The CDK5 expression was detected in 494 cases and 
53.8  % tissues showed positive CDK5 expression. The 
pattern of CDK5 expression revealed by immunohisto-
chemical analysis was illustrated in Fig.  1. The positive 
rates of CDK5 were 27.8, 31.0, 50, 54.0, 58.8, 62.7  % in 
chronic cervicitis, CA, carcinoma in  situ, adenocarci-
noma, adenosquamous carcinoma and SCC, respectively 
(Table 1). The expression of CDK5 was lower in non-cer-
vical cancer tissues (29.2 %) compared with cervical can-
cer tissues (59.8 %) (P < 0.001) (Fig. 2a). CDK5 expression 
in the group with lymph node metastasis (86.5  %) was 
higher than that in the non-lymph node metastasis group 
(51.5 %) (P < 0.001) (Fig. 2b), indicating that CDK5 up- 
regulation may be relative to the carcinogenesis and pro-
gression of cervical cancer. The positive expression rate 
of CDK5 in advanced FIGO stage (86.5  %) was higher 
than early FIGO stage (51.5 %) (P < 0.001) (Fig. 2c). The 
expression of CDK5 in advanced TNM stage (stage II–
IV) grading (88.4  %) was higher than stage 0 (50.0  %), 
stage I (48.4  %) (P  <  0.001) (Fig.  2d). CDK5 positive 
expression level with pathological grade III (75.9 %) was 
higher than pathological grade I (42.9 %) and pathologi-
cal grade II (51.0 %) (P < 0.001) (Fig. 2e). 
The correlation between CDK5 expression 
and clinicopathological factors in cervical tissues
The correlations between CDK5 and selected variables 
were shown in Table  2. CDK5 had a positive relation-
ship with lymph node metastasis (r = 0.317; P < 0.001). 
Further, the relationships between CDK5 with histo-
logical type(r = 0.198; P < 0.001), FIGO stage(r = 0.358; 
P < 0.001), TNM stage(r = 0.329; P < 0.001) and patho-
logical grade(r = 0.259; P < 0.001) had also been found in 
this analysis.
Relationship between CDK5 expression 
and clinicopathological factors in different histological 
type of cervical cancer
Table  3 showed the relationships of CDK5 expression 
with clinicopathological variables in adenocarcinoma. 
CDK5 had a relationship with age (P  =  0.021). Also, 
CDK5 expression had no association with lymph node 
metastasis, FIGO stage, TNM stage and pathological 
grade (all P > 0.05) in adenocarcinoma.
Table  4 showed the relationships of CDK5 expres-
sion with clinicopathological variables in SCC. CDK5 
expression in patients without lymph node metasta-
sis (52.3  %) was lower than with lymph node metasta-
sis (91.4 %) (P < 0.001). In advanced TNM stage, CDK5 
expression (92.7  %) was higher than early TNM stage 
(49.2 %) (P < 0.001). In early FIGO stage, the expression 
of CDK5 (52.3 %) was lower than advanced FIGO stage 
(91.4  %) (P <  0.001). The expression of CDK5 in differ-
ent pathological grades was statistically significantly dif-
ferent (P < 0.001). The positive relationships were found 
between CDK5 and lymph node metastasis (P <  0.001), 
FIGO stage (P < 0.001), TNM stage (P < 0.001) and path-
ological grade (P < 0.001) in SCC.
Table  5 showed the relationships of CDK5 expression 
with clinicopathological variables in adenosquamous 
carcinoma. In advanced TNM stage, CDK5 expression 
(90.0  %) was higher than early TNM stage (45.8  %) in 
adenosquamous carcinoma (P = 0.019). TNM stage was 
positively interrelated to CDK5 (P  =  0.019) in adenos-
quamous carcinoma.
Discussion
In this study, we investigated the differential expression 
level of CDK5 in patients with cervical cancer and pre-
cancerous lesions so as to clarify the correlation between 
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CDK5 and carcinogenesis and progression of cervical 
cancer.
Cervical cancer is one of the most common gynecolog-
ical cancers, which has constituted a serious threat to the 
life and health of women [16, 17]. The complex patho-
genesis of cervical cancer has not been clearly defined 
nowadays. And it is believed that the tumor genesis is a 
process of multifactor, polygenic and multi-step, which is 
still an attractive area worth exploring [18].
The abnormal regulation of cell cycle is known to play 
an essential role in the genesis of tumor. CDK is a class 
of serine/threonine protein kinases, which participate 
in the regulation of cell cycle. CDK5 is a member of 
CDKs family, but in comparison with the other CDK, it 
is not a cyclin-dependent kinase, nor directly is involved 
in the regulation of the cell cycle. Previous studies of 
CDK5 mainly focused on the neurological disorders, 
such as Alzheimer’s disease [19]. In recent years, stud-
ies have found that CDK5 was not only expressed in 
neurons, but also turned out to be of particular impor-
tance in non-neuronal cells, for instance: immune 
cells, endothelial cells, epithelial cells, tumor cells and 
so on. And in some studies, CDK5 was associated with 
the development of several cancers, such as lung can-
cer [20], breast cancer [21], prostate cancer [22] and 
Table 1 Relationship of CDK5 expression with other clinicopathological variables
CA condyloma acuminates, SCC squamous cell carcinoma, FIGO International Federation of Gynecology and Obstetrics, TNM tumor node metastasis
a Two independent-samples Chi-square test was performed
b Kruskal–Wallis H test was performed
Characteristic Total number No. patients, stratified by CDK5 Z P value
Negative (228) Positive (266)
Age −1.557 0.120a
 ≤44 263 130 (49.4 %) 133 (50.6 %)
 >44 231 98 (42.4 %) 133 (57.6 %)
Lymph node metastasis −5.998 <0.001a
 Negative 264 128 (48.5 %) 136 (51.5 %)
 Positive 96 13 (13.5 %) 83 (86.5 %)
Histological type 32.490 <0.001b
 Chronic cervicitis 54 39 (72.2 %) 15 (27.8 %)
 CA 42 29 (69.0 %) 13 (31.0 %)
 Carcinoma in situ 38 19 (50.0 %) 19 (50.0 %)
 Adenocarcinoma 63 29 (46.0 %) 34 (54.0 %)
 SCC 263 98 (37.3 %) 165 (62.7 %)
 Adenosquamous carcinoma 34 14 (41.2 %) 20 (58.8 %)
FIGO stage −5.998 <0.001a
 I–II 264 128 (48.5 %) 136 (51.5 %)
 III–IV 96 13 (13.5 %) 83 (86.5 %)
TNM stage 52.911 <0.001b
 0 38 19 (50.0 %) 19 (50.0 %)
 I 248 128 (51.6 %) 120 (48.4 %)
 II–IV 112 13 (11.6 %) 99 (88.4 %)
Pathological grade 23.604 <0.001b
 I 28 16 (57.1 %) 12 (42.9 %)
 II 157 77 (49.0 %) 80 (51.0 %)
 III 141 34 (24.1 %) 107 (75.9 %)
Table 2 The correlation between  CDK5 expression 
and clinicopathological factors in cervical tissues
FIGO International Federation of Gynecology and Obstetrics, TNM tumor node 
metastasis
Variable r P
Lymph node metastasis 0.317 <0.001
Histological type 0.198 <0.001
FIGO stage 0.358 <0.001
TNM stage 0.329 <0.001
Pathological grade 0.259 <0.001
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neuroendocrine thyroid cancer [23]. These findings sug-
gested that CDK5 could be of importance in the cancers 
tissues.
In this study, we primarily used IHC method to detect 
the expression of CDK5 in cervical cancer tissues and 
precancerous lesions, and analyzed its potential role 
Table 3 Relationship of CDK5 expression with other clinicopathological variables in adenocarcinoma
FIGO International Federation of Gynecology and Obstetrics, TNM tumor node metastasis
a Two independent-samples Chi square test was performed
b Kruskal–Wallis H test was performed
Characteristic Total number No. patients, stratified by CDK5 Z P value
Negative (29) Positive (34)
Age −2.316 0.021a
 ≤44 27 17 (63.0 %) 10 (37.0 %)
 >44 36 12 (33.3 %) 24 (66.7 %)
Lymph node metastasis −1.269 0.205a
 Negative 18 6 (33.3 %) 12 (66.7 %)
 Positive 45 23 (51.1 %) 22 (48.9 %)
FIGO stage −1.269 0.205a
 I–II 45 23 (51.1 %) 22 (48.9 %)
 III–IV 18 6 (33.3 %) 12 (66.7 %)
TNM stage
 I 43 23 (53.5 %) 20 (46.5 %) 2.983 0.084a
 II–IV 20 6 (30.0 %) 14 (70.0 %)
Pathological stage 5.455 0.065b
 I 10 6 (60.0 %) 4 (40.0 %)
 II 38 20 (52.6 %) 18 (47.4 %)
 III 15 3 (20.0 %) 12 (80.0 %)
Table 4 Relationship of CDK5 expression with other clinicopathological variables in SCC
FIGO International Federation of Gynecology and Obstetrics, TNM tumor node metastasis
a Two independent-samples Chi-square test was performed
b Kruskal–Wallis H test was performed
Characteristic Total number No. patients, stratified by CDK5 Z P value
Negative (98) Positive (165)
Age −1.167 0.243a
 ≤44 138 56 (40.6 %) 82 (59.4 %)
 >44 125 42 (33.6 %) 83 (66.4 %)
 Lymph node metastasis −5.785 <0.001a
 Negative 193 92 (47.7 %) 101 (52.3 %)
 Positive 70 6 (8.6 %) 64 (91.4 %)
FIGO stage −5.785 <0.001a
 I–II 193 92 (47.7 %) 101 (52.3 %)
 III–IV 70 6 (8.6 %) 64 (91.4 %)
TNM stage
 I 181 92 (50.8 %) 89 (49.2 %) 45.53 <0.001a
 II–IV 82 6 (7.3 %) 76 (92.7 %)
Pathologicl grade 16.909 <0.001b
 I 18 10 (55.6 %) 8 (44.4 %)
 II 119 57 (47.9 %) 62 (52.1 %)
 III 126 31 (24.6 %) 95 (75.4 %)
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Table 5 Relationship of CDK5 expression with other clinicopathological variables in adenosquamous carcinoma
ND no data, FIGO International Federation of Gynecology and Obstetrics, TNM tumor node metastasis
a Two independent-samples Chi-square test was performed
Characteristic Total number No. patients, stratified by CDK5 Z P value
Negative (14) Positive (20)
Age −0.122 0.918a
 ≤44 19 8 (42.1 %) 11 (57.9 %)
 >44 15 6 (40.0 %) 9 (60.0 %)
Lymph node metastasis −1.857 0.120a
 Negative 26 13 (50.0 %) 13 (50.0 %)
 Positive 8 1 (12.5 %) 7 (87.5 %)
FIGO stage
 I–II 26 13 (50.0 %) 13 (50.0 %) −1.857 0.120a
 III–IV 8 1 (12.5 %) 7 (87.5 %)
TNM stage
 I 24 13 (54.2 %) 11 (45.8 %) 5.518 0.019a
 II–IV 10 1 (10.0 %) 9 (90.0 %)
Fig. 1 Immunohistochemical analysis of CDK5 expression in cervical cancer. a and b showed that CDK5 expressed strongly in adenocarcinoma. The 
area of the square in a represented b. c and d showed strong CDK5 expression in squamous carcinoma. The area of the square in c represented d.
The original magnification of a and c was ×100. The original magnification of b and d was ×400
Page 7 of 10Pan et al. Eur J Med Res  (2016) 21:28 
in the tumor genesis of cervical cancer. Our results 
showed that CDK5 expression level was remarkably 
higher in cervical cancer tissues (59.8  %) compared 
with non-cancer tissues (29.2  %) (P <  0.001), indicat-
ing that CDK5 up-regulation may be relative to the car-
cinogenesis and progression of cervical cancer. We also 
investigated the corrections between CDK5 and clin-
icopathological variables. However, these clinicopatho-
logical variables, such as pathological grade, lymph 
node metastasis and FIGO stage above only showed 
weak relevance with SCC, thus, the relationship 
between CDK5 expression and the clinicopathological 
Fig. 2 Relationship between CDK5 expression and some clinicopathological features in cervical tissues. a Tissue; b Lymph node metastasis; c FIGO 
stage; d TNM stage; e Pathological grade
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parameters needs to be confirmed with larger sample 
size.
Currently, there are merely two researches on CDK5 
in cervical cancer. A study reported that CDK5 had a 
role in decreasing the growth of human cervical cancer 
cell line when retinoic acid treatment was applied to use 
and the expression of CDK5 and p35 were up-regulated 
by retinoic acid treatment [12]. So the study conferred 
CDK5 and p35 could have a positive effect on the retinoic 
acid-induced HeLa apoptosis [12]. Furuya et al. [24] also 
performed a study on HeLa cells and showed that CDK5 
was linked to endocytic sorting and autophagy. CDK5/
p25 is able to phosphorylate vacuolar protein sorting 
34 (Vps34) at Thr159 site, which hinders Vps34 interac-
tion with Beclin-1 during mitosis and finally blocks the 
autophagy. But there is no available research about CDK5 
expression level and mechanisms in cervical cancer tis-
sues and precancerous lesions. The genesis of cancer 
was closely correlated with abnormal regulation of DNA 
damage and repair. A research stated that CDK5 was 
mandatory for the DNA damage response in tumor cells 
[25] and another study showed that CDK5/STAT-3 onco-
genic pathway played a key role in the expression of DNA 
repair genes [26].
Besides the expression of CDK5 in cervical cancer tis-
sues, we further investigated the correlation between 
CDK5 expression and clinicopathological factors, which 
could reflect the deterioration and development of cer-
vical cancer. For instance, higher CDK5 expression 
was found to be correlated with advanced FIGO stage, 
advanced TNM stage and lymph node metastasis. These 
results indicated that CDK5 might be a potential pre-
dictor for the deterioration and development of cervical 
cancer. Similar trend was reported in non-small cell lung 
cancer that CDK5 expression was associated with dif-
ferentiation, lymph node metastasis and overall survival 
[20]. Thus, CDK5 may play consistent oncogenic roles in 
cervical carcinoma and non-small cell lung cancer. How-
ever, the role of CDK5 expression in the survival estima-
tion needs further investigation.
Further, the results showed that higher CDK5 expres-
sion in cervical cancer with lymph node metastasis has 
some similarities with studies in other malignancies. 
For example, Liu et al. [20] examined CDK5 expression 
in 95 patients with non-small cell lung cancer (NSCLC). 
They found no association between CDK5 expression 
and clinicopathological features, such as the time of sur-
gery, age, and gender of the patients or histopathology 
grading. However, significant correlations were observed 
between CDK5 expression and the degree of differentia-
tion, the pathological stage, and lymph node metastases. 
More importantly, patients with CDK5-positive had a 
poor 5-year overall survival compared to CDK5-negative 
patients in NSCLC. CDK5 was reported to be involved 
in the regulation of proliferation and survival of breast 
cancer cells, and CDK5 was characterized as a down-
stream target of extracellular regulated protein kinases 
in carboplatin-induced cell death [27, 28]. The usage of 
shRNA technology or inhibitors to block the expression 
of CDK5 in pancreatic cancer cells could dramatically 
inhibit the growth of MIApaCa-2 cells, thereby reduc-
ing the incidence of tumor development [29]. Further, 
CDK5 controlled cell growth, migration and metasta-
sis, and was indirectly involved in the regulation of cell 
cycle, which might contribute to the development of 
prostate cancer [30]. Besides, the inhibition of CDK5 
either via shRNA or by its pharmacological inhibitor 
roscovitine could reduce the migration and growth of 
medullary thyroid carcinoma cells in vitro [31]. We con-
jectured that the role of CDK5 involved in the prolifera-
tion, migration and apoptosis of other tumors cells may 
provide clues to the ascertainment of its contribution in 
cervical cancer.
Our results showed that CDK5 expression had a close 
relationship with lymph node metastasis (r  =  0.317, 
P  <  0.001). The mechanism of CDK5 influencing the 
lymphatic metastasis remains unknown in cervical car-
cinoma. However, some similar studies in other disease 
could provide a hint. Oncogenic epithelial–mesenchymal 
transition (EMT) refers to the process in which epithe-
lial malignant cells acquire mesenchymal cell phenotype, 
including enhanced migratory capacity and invasive-
ness, and is generally accepted as a mechanism underly-
ing metastasis in many types of cancers [32], and so as 
in cervical cancer [33]. High expression of CDK5 or p35 
had been demonstrated to be involved in the cancer cell 
motility and metastasis potential via EMT, such as in 
breast cancer [21], lung cancer [34], and head and neck 
squamous cell carcinoma [35]. In cervical cancer, the 
expression of miR-21 was up-regulated [36]. MiR-21 plays 
an important role in regulating biological behaviors in 
many malignancies. And miR-21 is associated with tumor 
biological behaviors, including apoptosis [37], lymph 
node metastasis [38], EMT [39], migration and invasion 
[34]. Study has shown that the expression of miR-21 and 
CDK5 were correlated with lymph node metastasis in 
head and neck squamous cell carcinoma [35]. In breast 
cancer, miR-21/CDK5 axis was abnormal activated 
which had an association with lymph node metastasis 
[38]. Though expression of CDK5 was detected in cervi-
cal cancer tissue and regulative mechanism of CDK5 was 
investigated in other cancers, the probable mechanism 
between CDK5 and lymph node metastasis in cervical 
cancer still needs further confirmation.
Based on our observations, we speculated that the up-
regulated expression of CDK5 from precancerous lesions 
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to cervical cancer tissues might be intimately correlated 
with the development of cervical carcinoma.
Conclusions
In summary, the present study confirmed a higher 
expression level of CDK5 in cervical cancer tissues 
compared with precancerous lesions. These results may 
break new ground in the exploration of biologic behav-
ior in cervical cancer. And CDK5 may become a new bio-
marker or molecular target for the treatment of cervical 
cancer. The clinical role of CDK5 in cervical cancer may 
be better defined with a larger sample size, and a long 
follow-up prognosis analysis is extraordinarily necessary. 
Therefore, future in  vitro and in  vivo studies to explore 
the carcinogenesis mechanism of CDK5 in cervical can-
cer is warranted. CDK5 may play an essential role in the 
development of cervical cancer and it may be useful for 
the clinical diagnosis, treatment and prognosis evalua-
tion of cervical cancer.
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